| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Michael Grosse CEO | XETRA Exchange | DE0007165631 ISIN |
| DE Country | 13,573 Employees | 27 Mar 2026 Last Dividend | 13 Jun 2016 Last Split | - IPO Date |
Sartorius Aktiengesellschaft, with its foundation stretching back to 1870, is a leading provider of cutting-edge bioprocess solutions and laboratory products and services on a global scale. Headquartered in Göttingen, Germany, the company has carved a niche in supporting the life science research and biopharmaceutical manufacturing sectors, alongside contributing significantly to pharmaceutical quality control, cell and gene therapy, and applied industries. With a rich heritage and a vision focused on facilitating scientific innovation, Sartorius aims to simplify the lab and manufacturing processes, thereby accelerating the development of therapeutic drugs and vaccines that are vital for healthcare advancements.
Under its comprehensive portfolio, Sartorius Aktiengesellschaft offers a wide array of products and services tailored to meet the diverse needs of its clientele, encompassing everything from the initial stages of research to full-scale biomanufacturing processes.